| Previous Close | 39.05 |
| Open | 38.96 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 38.71 - 38.98 |
| 52 Week Range | 37.20 - 44.54 |
| Volume | 2,460,202 |
| Avg. Volume | 2,745,380 |
| Market Cap | 92.73B |
| Beta | 0.98 |
| PE Ratio (TTM) | 43.64 |
| EPS (TTM) | 0.89 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Dividend & Yield | 1.99 (5.12%) |
| Ex-Dividend Date | 2017-08-09 |
| 1y Target Est | 48.00 |
- Zacks•2 days ago
Mylan Finalizes Settlement Agreement with DOJ for $465M
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
- Financial Times•3 days ago
[$$] The questionable strategy of a pharmaceuticals CEO
Sir, Joining in the discussion about GlaxoSmithKline's new plans, I find chief executive Emma Walmsley's strategic thinking on research and development questionable. I suggest it shows the terrible consequences ...
- TheStreet.com•5 days ago
Shire Gains as it Seeks European Approval For Dry Eye Treatment
The drug would be the first such treatment in Europe.
